Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020.

Maliepaard, M; Carree, W; van Bussel, M T J

Maliepaard, M; Carree, W; van Bussel, M T J.

Afiliação

Maliepaard M; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands; Department of Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Carree W; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands.
van Bussel MTJ; College ter Beoordeling van Geneesmiddelen, Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands. Electronic address: m.v.bussel@cbg-meb.nl.

ESMO Open ; 6(6): 100301, 2021 12.

Article em En | MEDLINE | ID: mdl-34752995

Assuntos

Antineoplásicos; Anticorpos Monoclonais; Antineoplásicos/efeitos adversos; Humanos; Inibidores de Proteínas Quinases

Palavras-chave

anticancer agents; dose selection; tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google